

# **UNICREDIT**

## **NEUTRAL**


Sector: Banks Price: Eu60.19 - Target: Eu61.00

## **Deploying Capital Through Strategic Equity Stakes**

Fabrizio Bernardi +39-02-77115.387 fabrizio.bernardi@intermonte.it Lorenzo Giacometti: +39-02-77115.244 lorenzo.giacometti@intermonte.it

| Stock Rating       |       |                     |       |  |
|--------------------|-------|---------------------|-------|--|
| Rating:            |       | Unchanged           |       |  |
| Target Price (Eu): | :     | from 52.00 to 61.00 |       |  |
|                    | 2025E | 2026E               | 2027E |  |
| Chg in Adj EPS     | 8.6%  | 7.9%                | 11.6% |  |

### **UNICREDIT - 12M Performance**



| Stock Data              |      |             |         |  |
|-------------------------|------|-------------|---------|--|
| Reuters code:           |      |             | CRDI.MI |  |
| Bloomberg code:         |      | UCG IM      |         |  |
| Performance             | 1M   | 3M          | 12M     |  |
| Absolute                | 9.4% | 20.6%       | 54.3%   |  |
| Relative                | 4.6% | 8.8%        | 37.1%   |  |
| 12M (H/L)               |      | 61.12/32.60 |         |  |
| 3M Average Volume (th): |      | 5.571.66    |         |  |

| Shareholder Data          |        |
|---------------------------|--------|
| No. of Ord shares (mn):   | 1,558  |
| Total no. of shares (mn): | 1,470  |
| Mkt Cap Ord (Eu mn):      | 93,756 |
| Total Mkt Cap (Eu mn):    | 93,756 |
| Mkt Float - Ord (Eu mn):  | 75,069 |
| Mkt Float (in %):         | 80.1%  |
| Main Shareholder:         |        |
| Blackrock                 | 5.9%   |
| Balance Sheet Data        |        |
|                           |        |

| Balance Sheet Data       |        |  |  |
|--------------------------|--------|--|--|
| Tangible Equity (Eu mn): | 61,913 |  |  |
| TEPS (Eu):               | 42.13  |  |  |
| CET1 Ratio Fully Loaded: | 15.1%  |  |  |
| Gross NPE Ratio:         | 2.7%   |  |  |

Yesterday UCG published its 2Q25 results, beating both our estimates and consensus due to the booking of some notable one-offs. We welcome the guidance upgrade, especially on 2027 (which now includes the consolidation of the stakes in Alpha and CBK), and also the strategy to deploy part of UCG's excess capital. However, given our updated estimates, we see no meaningful upside on the stock. We therefore stick to our NEUTRAL recommendation, while lifting our target price to €61.

- 2Q25 results: while the headlines show UniCredit's 2Q25 results beat estimates, this was driven by sizeable one-offs; underlying performance, stripping out the CBK-related hedging effect on trading, fell slightly short of expectations. The top line slipped QoQ (-2.7% A/E): NII held steady despite the Euribor downturn, fee income lagged as macro uncertainty weighed on Advisory & Financing, trading was dented by the CBK hedge, and dividend flows from strategic stakes only offered partial relief. OpEx were broadly flat QoQ (-1.5% A/E), marginally higher YoY on scope changes, yielding a cost/income ratio of 37.8% and an operating profit of €3.8bn, roughly 10% lower QoQ (-3.4% A/E). Below the line, credit quality remained benign, with a 10bp CoR and overlays unchanged at €1.7bn, while two non-distributable gains the revaluation of life-insurance JVs and the badwill from consolidating the 9.9% Commerzbank stake boosted the bottom line. Consequently, net profit reached €3.3bn. The CET1 ratio ticked down QoQ, reflecting a slight rise in RWAs and the accrual of nearly all distributable net profit (about €5.2bn in 1H).
- **Guidance:** UCG has lifted its FY25 targets, now guiding for roughly €10.5bn in net profit, while shareholder remuneration is set at ≥€9.5bn. Looking further ahead, FY27 ambitions have been upgraded to feature net profit ≥€11bn, while cumulative FY25-27 distributions are projected at no less than €30bn.
- Change in estimates: we are revising our model to incorporate the most recent quarterly disclosures: contributions from the strategic stakes in CBK and Alpha are now booked under Other Income after deducting the CBK hedging costs, lifting our FY25/26/27 projections by 0.8%, 2.6% and 3.5% respectively. We are trimming our LLP assumptions to reflect a CoR trajectory consistent with UCG's outlook, while one-off items expected in 2025 are now included. On capital, the CET1 ratio now captures the deductions arising from equity consolidation of CBK and Alpha. These changes translate into an uplift in adjusted net profit of 8.9%/8.0%/11.4% for FY25/26/27, leaving our earnings path broadly in line with the company's freshly upgraded 2025 guidance and its 2027 ambitions. Our remuneration framework assumes a 50% cash pay-out of adj. net profit complemented by a recurring share buyback equal to 45% of the same earnings measure.
- Valuation (NEUTRAL, TP €61): we value UCG using a Gordon Growth implicit P/TE model. Given the change in estimates outlined above, and the reduction of the ERP to 5.5%, we are raising our target price from €52 to €61. We stick to our NEUTRAL recommendation due to the lack of upside potential. The stock is trading at 1.43/1.34/1.24x its FY25/26/27, vs. 1.44/1.35/1.26x at target.

| Key Figures & Ratios         | 2023A  | 2024A  | 2025E  | 2026E  | 2027E  |
|------------------------------|--------|--------|--------|--------|--------|
| Total income (Eu mn)         | 23,826 | 24,844 | 24,752 | 25,248 | 25,929 |
| Net Operating Profit (Eu mn) | 14,366 | 15,439 | 15,239 | 15,752 | 16,418 |
| Net Profit Adj (Eu mn)       | 8,844  | 9,336  | 10,573 | 10,428 | 11,070 |
| EPS New Adj (Eu)             | 5.166  | 5.993  | 7.194  | 7.497  | 8.442  |
| EPS Old Adj (Eu)             | 5.166  | 5.993  | 6.625  | 6.947  | 7.567  |
| DPS (Eu)                     | 1.761  | 2.395  | 3.297  | 3.748  | 4.221  |
| P/E Adj                      | 11.7   | 10.0   | 8.4    | 8.0    | 7.1    |
| Div. Yield                   | 2.9%   | 4.0%   | 5.5%   | 6.2%   | 7.0%   |
| P/TE                         | 1.67   | 1.56   | 1.43   | 1.34   | 1.24   |
| ROTE                         | 14.3%  | 15.5%  | 17.1%  | 16.6%  | 17.4%  |

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein, and any of its parts, is strictly prohibited. None of the contents of this document may be shared with third parties without Company authorization. Please see important disclaimer on the last page of this report



#### IMPORTANT DISCLOSURES

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte

authorisation from internential internential internential internential internential internet exclusively at market professional and other institutional investors (Institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any investment or service to which this report may relate will not be made available to Non-Institution.

The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by Intermente. In the event that there be any doubt as to their reliability, this will

be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a solicitation to buy or

This disclaimer is constantly updated on Intermonte's website www.intermonte.it under LEGAL NOTICES, Valuations and recommendations can be found in the text of the most recent research and/or reports on the companies in question. For

Inis disclaimer is constantly updated on intermontes website www.intermontes.it under LESAL NOTICES. Valuations and recommendations can be round in the text of the most recent research and/or reports on the companies in question. For a list of all recommendations made by Intermonte on any financial instrument or issuer in the last twelve months consult the web page CUSTOMER AREA.
Intermonte distributes research and engages in other approved activities with respect to Major U.S. Institutional Investors ("Majors") and other Qualified Institutional Buyers ("QIBS"), in the United States, via Plural Securities LLC under SEC
15a-6 guidelines. Intermonte is not registered as a broker dealer in the United States under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not a member of the Securities Investor Protection Corporation ("SIPC"). Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC.

ANALYST CERTIFICATION

For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securities. The analyst (s) also certify that no part of their compensations was, is or will be directly or indirectly related to the specific recommendation or view in this report.

The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon variet factors, including intermonter's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities. Intermonte's internal procedures and codes of conduct are aimed to ensure the impartiality of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are made.

The analyst responsible for the report is not a) a resident of US; b) an associated person of a U.S. broker-dealer; c) supervisory principal of a U.S. broker-dealer. This Research Report is distributed in the U.S. through Plural Securities LLC, 950 3rd Avenue, Suite 1702, NY 10022, USA.

#### **GUIDE TO FUNDAMENTAL RESEARCH**

methods used to evaluate financial instruments and set a target price for 12 months after the investment recommendation are as follows:

- Discounted cash flow (DCF) model or similar methods such as a dividend discount model (DDM)

  Comparison with market peers, using the most appropriate methods for the individual company analysed: among the main ratios used for industrial sectors are price/ earnings (P/E), EV/EBITDA, EV/EBIT, price /sales
- Return on capital and multiples of adjusted net book value are the main methods used for banking sector stocks, while for insurance sector stocks return on allocated capital and multiples on net book value and embedded portfolio value

are used

For the utilities sector comparisons are made between expected returns and the return on the regulatory asset base (RAB)

Some of the parameters used in evaluations, such as the risk-free rate and risk premium, are the same for all companies covered, and are updated to reflect market conditions. Currently a risk-free rate of 4.0% and a risk premium between 5.5% - 6.0% are being used.

#### Frequency of research: quarterly

Reports on all companies listed on the FTSEMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow

Reports on all companies listed on the FTSEMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow. A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published. Explanation of our ratings system:

BUY: stock expected to outperform the market by over 25% over a 12 month period;

OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period;

NEUTRAL: stock performance expected at between +10% and - 10% compared to the market over a 12 month period;

NUNDERPERROM: stock expected to underperform the market by between -10% and -25% over a 12 month period; SELL: stock expected to underperform the market by over 25% over a 12 month period; Prices: The prices reported in the research refer to the price at the close of the previous day of trading

#### CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS

Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms

As at 24 July 2025 Intermonte's Research Department covered 134 companies. Intermonte's distribution of stock ratings is as follows:

32.84% OUTPERFORM: 38.06% NEUTRAL 29.10% UNDERPERFORM: 00.00% SELL: 00.00%

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (79 in total) is as follows:

53.16% OUTPERFORM: 29.11% NEUTRAL 17.73% UNDERPERFORM: SELL:

### CONFLICT OF INTEREST

CONTLIC OF MICRES 1
In order to disclose its possible conflicts of interest Intermente SIM states that:
Intermente SIM S.p.A. operates or has operated in the last 12 months as the person in charge of carrying out the share buyback plan approved by the shareholders' meeting of ABITARE IN, ANIMA HOLDING, AZIMUT, CIVITANAVI SYSTEMS, ELLEA, INTERE, PHARMANUTRA, SERVIZI ITALIA, SESA, STAR7, TMP GROUP, UNIDATA, VALSOIA, WEBUILD
Intermente SIM S.p.A. provides or has provided corporate brokerage services to ALLCORE, AMNAWAYE, ANITARES VISION, AQUAFIL, AVIO, CASTA DIVA GROUP, CUBE LABS, CY4GATE, CYBEROO, DIGITOUCH, DOMINION HOSTING HOLDING, ELICA, ESPRINET, EVISSO, EXECUS, FINE FOODS & PHARMACEUTICALS NTIM, FNIM, FRANCHI UMBERTO MARMII, G.M. LEATHER, GPI, GREEN OLEO, GREENTHESIS, HIGH QUALITY FOOD, IGD, IKONISYS SA, INTRED, ISCC FINTECH, ITALIAN EXHIBITION GROUP, LEMON SISTEMI, LUVE, MAPS, MARE ENGINEERING GROUP, NEODECORTECH, NOTORIOUS PICTURES, PREATONI GROUP, REDFISH LONGTERM CAPITAL, REVO INSURANCE, REWAY GROUP, SERI INDUSTRIAL, SPINDOX, STAR7, TALEA

GROUP, LEMON SISTEMI, LUVE, MAPS, MARE ENGINEERING GROUP, NEODECORTECH, NOTORIOUS PICTURES, PREATONI GROUP, REDFISH LONGTERM CAPITAL, REVO INSURANCE, REWAY GROUP, SERI INDUSTRIAL, SPINDOX, STAR7, TALEA GROUP, USES BIOMED, XENIA HOTELLERIE SOLUTION, Zest Group Spa in the last 12 months as Financial Content Provider on the company ALLCORE, ALMAWAVE, B&C SPEAKERS, BANCA SISTEMA, BIFIRE, CASTA DIVA GROUP, CLEANBNB, COFLE, CROWDFUNDME, CUBE LABS, DIGITOUCH, DOMINION HOSTING HOLDING, ECOSUNTEK, EDILIZIACROBATICA, ELES, ENERGY, EVISO, ESCUS, FAE TECHNOLOGY, FIERA MILANO, FOPE, G.M. LEATHER, GREEN OLEO, HIGH QUALITY FOOD, IGD, IKONINSY SA, INTERCOS, INTERCO, INTERCO, ISCHIETCH, LEMON SISTEMI, ADSA JANAET REVINIEERING GROUP, MASI AGRICOLA, MASI AGRICOLA, DOSI AUTOMATION SYSTEMA, PREATONI GROUP, RACING FORCE, REDFISH LONGTERM CAPITAL, RETI, SCIUKER FRAMES, SG COMPANY, SIMONE, SOLID WORLD GROUP, SPINDOX, TALEA GROUP, TAMBURI, TINEXTA, TMP GROUP, TSP, ULISSE BIOMED, XENIA HOTELLERIE SOLUTION, Zest Group

Intermonte SIM S.p.A. performs or has performed in the last 12 months the role of intermediary appointed in the public purchase and/or exchange offer transaction of MARE ENGINEERING GROUP, TINEXTA Intermonte SIM S.p.A. operates or has operated in the last 12 months as liquidity provider of BANCA SISTEMA, Zest Group SpA Intermonte SIM is acting as counterparty to WIIT Fin S.r.I. in connection with call and put options having WIIT S.p.A. shares and dividends as reference underlying. Intermonte SIM acts as financial advisor to Banco BPM in the context of the offer promoted by Unicredit.

Intermonte Sim acts as EXM acts as EXM advisor to Banco Fibs in the ordinate of the ordinate o

ITALIA, FIELCOM ITALIA K, TENANIS, INCREDIT, UNIPOL, WEBUILD Intermonte Sim Sp.A. has or had in the last 12 months a marketing contract on instruments issued by BARCLAYS, BNP PARIBAS, GOLDMAN SACHS GROUP INC, LEONTEQ, MAREX FINANCIAL, MEDIOBANCA, MORGAN STANLEY, NATIXIS, SOCIETE GENERALE, UNICREDIT, VONTOBEL N, WISDOMTREE IRELAND LIMITED Intermonte SIM S.p.A. performs or has performed in the last 12 months the role of specialist on financial instruments issued by ABITARE IN, ALKEMY, BANCA IFIS, BANCA SISTEMA, CIVITANAVI SYSTEMS, COFLE, CYBEROO, DIGITOUCH, ECOSUNTEK, ELEN,, EMAK, ENERGY, GREEN OLEO, GREEN THESIS, MISITANO & STRACUZZI SPA, MONDADORI EDIT., OLIDATA, OMER, PHARMANUTRA, QF ALPHA IMM, REPLY, SERVIZI ITALIA, SESA, SG COMPANY, SOMEC, SYS-DAT, TAMBURI, TESMEC, THE ITALIAN SEA GROUP, TINEXTA, TMP GROUP, IXT E-SOLUTIONS, UNIDATA, WIIT with the obligation to disseminate studies Intermonte SIM S.p.A. plays or has played in the last 12 months the role of sponsor for UNIDATA S.p.A.

© Copyright 2025 by Intermonte SIM - All rights reserved
It is a violation of national and international copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM you are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM. INTERMONTE will take legal action against anybody transmitting/publishing its Research products without its express authorization.

INTERMONTE Sim strongly believes its research product on Italian equities is a value added product and deserves to be adequately paid.

Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONTE research product.

INTERMONTE SIM is MIFID compliant - for our Best Execution Policy please check our Website https://www.intermonte.it/it/avvertenze-legali/mifid-ii.html